Clinical Scorecard: Evaluation of Academic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Real-World Settings: A Prospective Cohort Analysis

At a Glance

Key Highlights

• Complete response achieved in 57.5% of patients
• 4-year event-free survival rate of 46.2 ± 6.3%
• 4-year overall survival rate of 67 ± 5.9%
• 83.3% complete response in patients with follicular lymphoma
• Cytokine release syndrome (CRS) detected in 43.4% of patients

Guideline-Based Recommendations

Diagnosis

• Confirm CD19 expression in tumor tissue prior to therapy initiation

Management

• Utilize academic CAR-T cell products as a cost-effective alternative for r/r BCL

Monitoring & Follow-up

• Monitor for cytokine release syndrome and neurotoxicity post-treatment

Risks

• Potential for cytokine release syndrome and neurotoxicity

Patient & Prescribing Data

76 patients with relapsed/refractory B-cell lymphomas

Academic CAR-T cell products can improve access and affordability

Clinical Best Practices

• Engage in a network of hospitals for CAR T-cell preparation and administration
• Ensure rigorous testing and regulatory oversight of academic CAR T-cell products

Related Resources & Content

• ClinicalTrials.gov Identifier